New England Journal of Medicine· 2013Q1
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- 3,364citations
- Q1SCImago
- 2013year
Short summary
Radium-223 dichloride, an alpha emitter targeting bone metastases, significantly improved overall survival by 3.7 months (14.9 vs. 11.3 months) in men with castration-resistant prostate cancer, compared to placebo, in a phase 3 trial (n=921).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine